Open-label extension study of Study M15-741 to evaluate the safety and tolerability of daily exposure for 24 hours of continuous subcutaneous infusion of ABBV-951 in patients with Parkinson's disease
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: ABBVIE DEUTSCHLAND GMBH & CON K.G
- Phase: III
- Execution start: 30/06/2020
- End of execution: 28/02/2023
- PI: FRANCISCO ESCAMILLA SEVILLA